Marinomed
Biopharmaceutical company focused on developing therapeutics in virology and immunology. Activities include discovery and translational research, development of solubilization technologies to enable aqueous formulations of poorly soluble APIs, formulation development for topical nasal and ophthalmic products, preclinical and clinical development up to Phase III, and licensing/partnerships for commercialization and technology transfer.
Industries
Nr. of Employees
small (1-50)
Marinomed
Hovengasse 25, 2100 Korneuburg, Austria
Patents
Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs
US-11510859-B2
View Details
Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs
US-11510859-B2
View DetailsProducts
Budesolv
Aqueous budesonide nasal formulation developed to increase solubility and bioavailability of a corticosteroid for allergic rhinitis; clinically evaluated in Phase III.
Tacrosolv
Ophthalmic tacrolimus solution formulated to enhance ocular tissue penetration and tolerability at low concentrations; clinical data reported from Phase II.
Satiasolv
Water‑based cannabidiol (CBD) formulation developed to improve solubility and enable alternative dosage options and targeted delivery (preclinical intranasal brain uptake data reported).
Budesolv
Aqueous budesonide nasal formulation developed to increase solubility and bioavailability of a corticosteroid for allergic rhinitis; clinically evaluated in Phase III.
Tacrosolv
Ophthalmic tacrolimus solution formulated to enhance ocular tissue penetration and tolerability at low concentrations; clinical data reported from Phase II.
Satiasolv
Water‑based cannabidiol (CBD) formulation developed to improve solubility and enable alternative dosage options and targeted delivery (preclinical intranasal brain uptake data reported).
Services
Provision of solubilization platform capabilities and collaborative formulation development services to external partners, including technology transfer and long‑term partnership arrangements.
Provision of solubilization platform capabilities and collaborative formulation development services to external partners, including technology transfer and long‑term partnership arrangements.
Expertise Areas
- Clinical trial management (Phase II/III)
- Formulation development for aqueous topical products (nasal, ophthalmic)
- Solubilization of poorly water‑soluble APIs
- Intranasal and ophthalmic drug delivery
Key Technologies
- Solubilization technologies for hydrophobic APIs (enabling aqueous formulations)
- Intranasal drug delivery and nasal-to-brain uptake studies
- Aqueous ophthalmic formulation technologies for low-dose delivery
- Water-based formulations for lipophilic compounds (e.g., cannabinoids)
News & Updates
Company filed for court restructuring proceedings without self‑administration.
Announcement of plan to apply for initiation of court restructuring proceedings without self‑administration.
Decision to conduct a cash capital increase to cover short‑term capital requirements of approximately EUR 2 million.
Announcement of a strategic partnership and worldwide licensing agreement for the company's solubilization technology applied to inhalation therapy.
Completion of a Phase III pivotal study validating an aqueous solubilized budesonide nasal formulation that met clinical endpoints.
Patent grant covering technology enabling generation of aqueous solutions from insoluble compounds.
Company filed for court restructuring proceedings without self‑administration.
Announcement of plan to apply for initiation of court restructuring proceedings without self‑administration.
Decision to conduct a cash capital increase to cover short‑term capital requirements of approximately EUR 2 million.
Announcement of a strategic partnership and worldwide licensing agreement for the company's solubilization technology applied to inhalation therapy.
Completion of a Phase III pivotal study validating an aqueous solubilized budesonide nasal formulation that met clinical endpoints.
Patent grant covering technology enabling generation of aqueous solutions from insoluble compounds.